Elicera Therapeutics is an innovative biotechnology company with a focus on immunotherapy against cancer. The company develops pioneering treatments based on CAR-T cell therapy and oncolytic viruses against cancer with strong support from international collaborations and significant soft financing.
The company has a solid pipeline of promising treatments. One of these is CAR-T cell therapy, where the patient's own immune cells are modified to attack cancer cells. This therapy has shown promising results, particularly against blood cancers, and Elicera Therapeutics is at the forefront of its fourth-generation CAR-T cell therapy. Another part is oncolytic viruses. These genetically modified viruses infect and destroy cancer cells, while activating the body's immune system to further fight the cancer.
Elicera Therapeutics is currently conducting two clinical trials with its oncolytic virus and CAR-T cell therapy, ELC-100 (phase I-IIa), ELC-301 (phase I-II). Elicera's unique platform, iTANK, strengthens the effectiveness of CAR-T cells and opens up lucrative partnerships and licensing agreements. With a strong financial position, Elicera Therapeutics is well positioned to take the next step in its development. ELC-100 cost is sponsored which shows the potential of it.
The company is being traded on Stockholm First north with ticker Elic, with a mcap of ~65 mSek with ~30 mSek in cash, insiders own 35% of company so limited free float, so the potential is really big here if you compare with valuation of other biotech's working in Car-T sector. Cash is excepted to take company into 2026, but as their are warrants Elicera TO1 out that is to be subscribed Q1 2025, the cash position will likely increase further thus no need of capital injection for long time.
shortterm triggers: Completion of ELC-100 phase 1 Q1-2025, First patient in on ELC-301 Q4-2024 and interim of three patients H1 2025. Both of these will be high drivers for the valuation if positive.
CEO has stated that they aim to outlicense their iTANK platform, and CEO hopes it will be attracting interest near term.
https://discord.gg/DXHVc6Sz link to community discord where more info can be found / asked for.
The company has a solid pipeline of promising treatments. One of these is CAR-T cell therapy, where the patient's own immune cells are modified to attack cancer cells. This therapy has shown promising results, particularly against blood cancers, and Elicera Therapeutics is at the forefront of its fourth-generation CAR-T cell therapy. Another part is oncolytic viruses. These genetically modified viruses infect and destroy cancer cells, while activating the body's immune system to further fight the cancer.
Elicera Therapeutics is currently conducting two clinical trials with its oncolytic virus and CAR-T cell therapy, ELC-100 (phase I-IIa), ELC-301 (phase I-II). Elicera's unique platform, iTANK, strengthens the effectiveness of CAR-T cells and opens up lucrative partnerships and licensing agreements. With a strong financial position, Elicera Therapeutics is well positioned to take the next step in its development. ELC-100 cost is sponsored which shows the potential of it.
The company is being traded on Stockholm First north with ticker Elic, with a mcap of ~65 mSek with ~30 mSek in cash, insiders own 35% of company so limited free float, so the potential is really big here if you compare with valuation of other biotech's working in Car-T sector. Cash is excepted to take company into 2026, but as their are warrants Elicera TO1 out that is to be subscribed Q1 2025, the cash position will likely increase further thus no need of capital injection for long time.
shortterm triggers: Completion of ELC-100 phase 1 Q1-2025, First patient in on ELC-301 Q4-2024 and interim of three patients H1 2025. Both of these will be high drivers for the valuation if positive.
CEO has stated that they aim to outlicense their iTANK platform, and CEO hopes it will be attracting interest near term.
https://discord.gg/DXHVc6Sz link to community discord where more info can be found / asked for.
Update regarding Elicera Therpeutics ticker ELIC:
First patient in on ELC-301 has completed and interim results of three patients is due Q1-2025, where safety and effect will already be measured, so according to CEO we might already see the anti-tumour effect at lowest dosage, which will be a high share price driver, and a 5 x share price rally H1 2025 would be possible given the already low valuation of the company.
https://www.redeye.se/video/event-presentation/1053807/elicera-therapeutics-ceo-jamal-el-mosleh-presents-at-redeye-investor-forum-in-gothenburg-nov-7-2024
here is link in Swedish where CEO presents the company and the latest clinical trial.
https://www.biostock.se/2024/11/eliceras-vd-en-av-de-storsta-milstolparna-i-var-historia/
Link in swedish to interview with CEO where he is very optimistic about the company.
First patient in on ELC-301 has completed and interim results of three patients is due Q1-2025, where safety and effect will already be measured, so according to CEO we might already see the anti-tumour effect at lowest dosage, which will be a high share price driver, and a 5 x share price rally H1 2025 would be possible given the already low valuation of the company.
https://www.redeye.se/video/event-presentation/1053807/elicera-therapeutics-ceo-jamal-el-mosleh-presents-at-redeye-investor-forum-in-gothenburg-nov-7-2024
here is link in Swedish where CEO presents the company and the latest clinical trial.
https://www.biostock.se/2024/11/eliceras-vd-en-av-de-storsta-milstolparna-i-var-historia/
Link in swedish to interview with CEO where he is very optimistic about the company.
